Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Amit Kumar is Chief Executive Officer at Anixa Biosciences. OQRO lists 7 transactions filed with the SEC under this name, the latest on Nov 2, 2026, each linked to the official Form 4.
Chief Executive Officer
Disclosures on record
7
Companies involved
1
10 buys, median −6.0 pts vs S&P 500, beat it 3 of 10 times.
Average −0.7 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Jan 15, 2025 to Aug 3, 2026, measured from the first close after the filing. Past results, not a forecast.
15 purchases disclosed; 30% of the 10 measured at 90 days finished ahead of the index. $1,000 placed after each of the 11 purchases disclosed since 2025-11-14 would be worth $9.4K today ($11K put in); the same in the S&P 500 (SPY): $11K.
Rank 42 of the 82 insiders with at least 10 purchases measured at 90 days. The middle of that group is −5.5 pts (median, against the S&P 500).
Anixa BiosciencesANIX
7 disclosures · Jan 2025 – Nov 2026 · 7 bought
Oct 30, 2026Bought~$16Kdisclosed Nov 2
DetailsOfficial recordOct 22, 2026Bought~$22K
DetailsEqual weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
Sep 24, 2026Bought~$19Kdisclosed Sep 28
DetailsOfficial recordJul 30, 2025Bought~$16Kdisclosed Jul 31
DetailsOfficial recordJul 11, 2025Bought~$16Kdisclosed Jul 14
DetailsOfficial recordJun 4, 2025Bought~$29Kdisclosed Jun 5
DetailsOfficial recordJan 15, 2025Bought~$96K
DetailsOfficial recordAmit Kumar bought shares on the open market in 14 different years since 2006 across 3 companies. Sales in 3 of the 21 years since 2006.
Amit Kumar reported 94 open-market purchases and 23 sales since 2006; purchases in 14 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $57K3×3 trades | — |
| 2025 | $156K4×4 trades | — |
| 2024 | $157K2×2 trades | — |
| 2023 | — | $42K1×1 trade |
| 2022 | $60K1×1 trade | — |
| 2021 | $132K5×5 trades | — |
| 2020 | $196K4×4 trades | — |
| 2019 | $101K3×3 trades | — |
| 2018 | $101K5×5 trades | — |
| 2017 | $18K4×4 trades | — |
| 2016 | $4.9K2×2 trades | — |
| 2015 | $185K23×23 trades | — |
| 2014 | $150K36×36 trades | — |
| 2008 | — | $6.7K2×2 trades |
| 2007 | —1×1 trade | — |
| 2006 | —1×1 trade | $443K20×20 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
As of the latest filing on , Amit Kumar reported holding 685,000 shares of Anixa Biosciences (ANIX), worth about $1.79M at the last close of $3 (Nov 13, 2026). In the last 12 months, Amit Kumar bought $57K in 3 open-market purchases.
Anixa Biosciences's proxy statement reports total compensation of $2.55M for Amit Kumar for fiscal year 2025, after $3.48M for 2024. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received. Proxy statement filed Jan 28, 2026
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Anixa Biosciences ANIX | 685,000 | 685K direct | $3 | $1.79M | Oct 30, 2026 |
Is this Amit Kumar’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
On the latest SEC Form 4, dated Oct 30, 2026, Amit Kumar reported holding 685,000 shares of Anixa Biosciences (ANIX). At the last close of $3 on Nov 13, 2026, that is about $1.79M. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, Amit Kumar reported 3 open-market purchases worth $57K, and no open-market sale. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Anixa Biosciences's proxy statement reports total compensation of $2.55M for Amit Kumar for fiscal year 2025, after $3.48M for 2024. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received.
Amit Kumar bought shares on the open market in 14 different years since 2006 across 3 companies. Sales in 3 of the 21 years since 2006.
In SEC filings since 2006: the latest open-market purchase is from 2026; the latest open-market sale is from 2023.
3 companies: Anixa Biosciences (ANIX, 2014–2026), Ascent Solar Technologies (ASTI, 2008), Acacia Research (ACTG, 2006–2007).
Amit Kumar reported 92 open-market purchases and 1 sale here, 2014 to 2026.
Amit Kumar reported 2 open-market purchases and 20 sales here, 2006 to 2007.
Amit Kumar reported 0 open-market purchases and 2 sales here, 2008.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
